CagriSema Beat High-Dose Semaglutide on HbA1c. The Margin Was Smaller Than the Headline

CagriSema has spent most of its public life framed as a weight-loss contender. A large phase 3 trial now gives it a different test: can adding the amylin analogue cagrilintide to semaglutide improve blood sugar more than high-dose semaglutide alone in people with type 2 diabetes?

The answer from REIMAGINE 2 is yes, but the size of that yes deserves attention. After 68 weeks, the combination lowered HbA1c by 1.91 percentage points, compared with 1.75 points for semaglutide 2.4 mg. The 0.16-point difference was statistically significant. It was also modest.

That tension is the story. CagriSema cleared its primary endpoint in a large, well-controlled trial. Yet the data do not support treating every numerical win as a clinical revolution.

What REIMAGINE 2 tested

REIMAGINE 2 was a randomized, double-blind, placebo-controlled and active-controlled phase 3 study conducted across 30 countries. It enrolled adults with type 2 diabetes whose HbA1c remained between 7.0% and 10.5% while taking metformin, with or without an SGLT2 inhibitor. Everyone also had overweight or obesity, defined in the study as a BMI of at least 25 kg/m2.

The trial randomized 2,713 people to seven treatment assignments that were pooled into six reported groups. The comparison that mattered most paired once-weekly cagrilintide 2.4 mg with semaglutide 2.4 mg and tested it against semaglutide 2.4 mg alone. Those groups included 603 and 605 participants, respectively. Other participants received cagrilintide alone, lower-dose versions of the combination or semaglutide, or placebo.

Mean HbA1c at baseline was 8.2%. The study ran for 68 weeks, long enough to move beyond the noisy first months of titration and see a sustained glycemic effect. Completion was high: 2,595 participants, or 95.7%, finished the study. At week 68, 2,376 participants, or 87.6%, were still on treatment.

Those retention numbers matter. A combination can look impressive in an idealized analysis but become less useful if many people cannot stay on it. REIMAGINE 2 still had treatment drop-off, but it did not lose most of its cohort along the way.

The primary result, without the sales gloss

Using the trial's efficacy estimand, mean HbA1c fell by 1.91 percentage points with CagriSema 2.4 mg plus 2.4 mg and by 1.75 points with semaglutide 2.4 mg. The estimated treatment difference was 0.16 percentage points in favor of CagriSema. The 95% confidence interval ranged from 0.05 to 0.27 points in favor of the combination, and the p value was 0.0035.

Statistically, that is a clean win. The confidence interval did not cross zero, and the prespecified primary endpoint favored the combination.

Clinically, the reading is less automatic. Both arms produced large HbA1c reductions from the same mean baseline. Adding cagrilintide improved the average result, but most of the measured glycemic change also occurred with semaglutide alone. Whether an extra 0.16 percentage points justifies another active drug will depend on the individual patient, including side effects, weight goals, cost, access, and the control already achieved on existing therapy. REIMAGINE 2 cannot settle all of those questions with one group average.

This is why the comparator matters. Beating placebo would show that CagriSema works. Beating semaglutide 2.4 mg asks a harder and more useful question: does the second pathway add anything to an already potent GLP-1 regimen? The trial says it does. It does not say the added benefit is enormous.

Why combine amylin and GLP-1?

Semaglutide activates the GLP-1 receptor. Cagrilintide is a long-acting amylin analogue. The combination is designed to use two hormonal systems that affect glucose regulation, appetite, and body weight.

That is a sensible pharmacologic idea, but a plausible mechanism is not the same as a proven clinical advantage. Combination drugs have to earn their complexity. They may improve efficacy, but they can also add tolerability problems and make it harder to know which component caused a given effect.

REIMAGINE 2 provides direct evidence for an incremental glycemic benefit. It also places a useful boundary around the claim. The trial supports CagriSema as more effective than semaglutide 2.4 mg for its primary HbA1c endpoint in this population. It does not prove that two-pathway treatment is better for every patient with type 2 diabetes, nor does the abstract establish cardiovascular or kidney protection.

The safety signal was familiar, not trivial

Adverse events were common across the active groups. They were reported by 86.9% of participants receiving high-dose CagriSema and 81.2% receiving semaglutide 2.4 mg. The corresponding rates were 82.2% with cagrilintide 2.4 mg, 81.6% with lower-dose CagriSema, 78.5% with semaglutide 1.0 mg, and 70.5% with pooled placebo.

Gastrointestinal disorders were the most common adverse events in the active-treatment groups. That fits the established tolerability pattern of therapies that act on GLP-1 and amylin pathways, but familiar side effects still count. Nausea, vomiting, constipation, or diarrhea can determine whether a medication remains usable outside a trial.

The abstract reports overall adverse-event rates, not a full patient-level account of severity, timing, or the trade-off between glycemic response and symptoms. Anyone evaluating the combination should look beyond the headline percentage and read the complete safety tables when they are available to them.

Two recent evidence reviews point in the same general direction. A systematic review of four randomized trials with 5,023 participants found that cagrilintide-based therapies reduced weight and improved some metabolic measures, while overall adverse events were more frequent than with placebo. A separate network meta-analysis covering six trials and 4,642 participants ranked high-dose amylin therapies among the stronger weight-loss options in its network. Its authors also described the evidence as sparse and low certainty and found more gastrointestinal adverse events with high-dose regimens, especially CagriSema and oral amycretin.

These reviews are useful context, not substitutes for REIMAGINE 2. They pool different populations, doses, and comparators. Their weight-loss rankings should not be pasted onto a glycemic trial as if every endpoint were interchangeable.

What the trial still cannot tell us

REIMAGINE 2 had scale, masking, an active comparator, and a prespecified primary endpoint. It also had limits.

First, the study was designed around HbA1c, not cardiovascular events, kidney failure, or mortality. A lower glucose measure can be valuable, but it is not proof of every downstream benefit associated with other drugs in the broader GLP-1 class.

Second, 81.3% of randomized participants were White. The study ran in 30 countries, yet the reported racial distribution still leaves questions about how well the average effect represents more diverse clinical populations.

Third, Novo Nordisk funded the trial. Several authors were company employees, and investigators disclosed relationships with multiple drug makers. Sponsor involvement does not erase a randomized result. It does make transparent methods, complete reporting, and independent analysis especially important.

Finally, a mean difference hides variation. Some patients may receive a larger added benefit from cagrilintide, while others may gain little beyond semaglutide or stop because of side effects. The published group result cannot identify those people in advance.

The Oria take

CagriSema passed a serious test. In 2,713 adults followed for 68 weeks, the high-dose combination lowered HbA1c more than high-dose semaglutide, and the result met conventional statistical standards.

The useful interpretation is narrower than the hype. The added average reduction was 0.16 percentage points. That is evidence of pharmacologic contribution, not evidence that semaglutide has suddenly become obsolete. The next practical question is not whether the p value was below 0.05. It is which patients gain enough from the second agent to make the added treatment burden worthwhile.

For now, REIMAGINE 2 moves CagriSema from an appealing two-hormone theory to a phase 3 combination with a verified glycemic advantage. It also reminds us that a positive trial can be both credible and incremental.

Sources

Buse JB and colleagues. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. Lancet Diabetes & Endocrinology, 2026. https://pubmed.ncbi.nlm.nih.gov/42251859/

Rao H and colleagues. Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis. Journal of Diabetes & Metabolic Disorders, 2026. https://pubmed.ncbi.nlm.nih.gov/42180166/

Kamrul-Hasan ABM and colleagues. Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis. Endocrinology, Diabetes & Metabolism, 2026. https://pubmed.ncbi.nlm.nih.gov/42175595/

Evidence grade: B. A large randomized, double-blind phase 3 trial directly supports the primary HbA1c claim, with high completion and an active high-dose semaglutide comparator. The grade stops at B because the average advantage was modest, long-term clinical outcomes were not tested in the reported primary analysis, the sponsor funded the study, and broader amylin evidence remains limited.

Medical disclaimer: This article is for education only and is not medical advice. CagriSema and the regimens discussed here should not be used, combined, or adjusted without guidance from a qualified clinician. People with diabetes need individualized treatment based on medical history, current medications, glucose patterns, side-effect risk, and access to regulated products. Oria exists to help readers examine peptide evidence and its limits, not to prescribe treatment or replace professional care.